Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy · Delayed Price · Currency is EUR | Market Cap | 10.25B -5.0% |
| Revenue (ttm) | 2.62B +11.8% |
| Net Income | 443.62M +6.5% |
| EPS | 2.12 +6.5% |
| Shares Out | 204.36M |
| PE Ratio | 23.64 |
| Forward PE | 20.16 |
| Dividend | 1.34 (2.68%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | 382,869 |
| Average Volume | 488,618 |
| Open | 50.00 |
| Previous Close | 50.00 |
| Day's Range | 50.00 - 50.85 |
| 52-Week Range | 43.76 - 55.35 |
| Beta | 0.53 |
| RSI | 64.57 |
| Earnings Date | Mar 19, 2026 |
About BIT:REC
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acety... [Read more]
Financial Performance
In 2025, BIT:REC's revenue was 2.62 billion, an increase of 11.82% compared to the previous year's 2.34 billion. Earnings were 443.62 million, an increase of 6.51%.
Financial StatementsNews
CVC Offers â¬10.9B Takeover for Recordati at 12% Premium
CVC Offers â¬10.9B Takeover for Recordati at 12% Premium
Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs
The head of Italian group Recordati expects treatments for rare diseases to be exempted from the 15% tariff the United States plans to impose on imported European pharmaceutical products, he said on W...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
Milan, 8 th May 2025 – The Board of Directors of Recordati S.p.A. approved the Group's Interim Report as of 31st March 2025, representing additional voluntary financial reporting(7). The Report was pr...
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
5 High-Quality Stocks in the Mediterranean
According to the High Quality Screener, a Premium All-in-One Screener template, five high-quality stocks based in Mediterranean countries are Diasorin SpA (MIL:DIA), Koza Altin Izletmeleri AS (IST:KOZ...